Splicing modulator antibody-drug conjugates and methods of use
US11352348B2 · kind B2 · utility
0Cited by
1References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 30, 2020 |
| Grant date | Jun 7, 2022 |
| Priority date | — |
| Expiry date | Nov 30, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.